// App-Quantinova.ai

: Which Asparaginase Formulation Retained Higher VTE Incidence Risk in Post Treatment Adult Acute Lymphoblastic Leukemia? a Meta-Analysis

Researchers

Presenter

  • Jack T Seki

Principal Investigators

  • Reem Alsibai

  • Ruiqi Chen

  • Eshetu G. Atenafu

  • Hassan Sibai

Medical Centers

  • Princess Margaret Cancer Center, University Health Network, Toronto, Canada

  • Evidence-Based Practice Research Program, Mayo Clinic, Rochester, MN, USA., Rochester, MN

  • University of Toronto, Toronto, Canada

  • Department of Medicine, University of Toronto, Toronto, Canada

  • University of Toronto - University Health Network-Princess Margaret Cancer Centre, TORONTO, Canada

Locations

  • Canada

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

  • Cardiovascular (CVS)

  • Oncology (ONC)

  • Blood/haematological Diseases

Disease

  • Acute lymphoblastic leukemia

  • Venous thrombosis

Biomarkers

  • N/A

Drug/Treatment

  • Asparaginase

Outcome

  • N/A

Study Design

  • Active Comparator

  • Single Arm

  • Prospective

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved